The global solid tumors drugs market to grow at a CAGR of 8.6% during the period 2016-2020.
The rising prevalence of various cancers, which has led to innovations and technological advancements, drives the development of new immunotherapy drugs that are more effective than the available drugs to treat solid tumors.
The report covers the present scenario and the growth prospects of the global solid tumors drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs, generics, and biosimilars used to treat solid tumors. It also considers the revenues to be generated from the sales of drugs that are anticipated to be launched into the market along with the decline in revenues from the patent expiries of the branded drugs during the forecast period.
A trend which is helping to boost market growth is the emergence of targeted and combination therapies. Targeted and combination therapies are being increasingly developed to treat solid tumors. Targeted therapies, which exploit the surface markers or properties of diseased or infected cells, cause fewer adverse effects than conventional non-targeted therapies.
For example, in 20% of the cases, breast cancer is associated with the overexpression of HER2, wherein drugs such as Kadcyla and Herceptin are administered as monotherapies or in combination. Targeting multiple pathways are known to reduce the risk of developing treatment-resistant disorders. Thus, combination therapies, which target distinct mechanisms, are highly efficacious in treating solid tumors.
According to the report, a key growth driver which is helping to boost market growth is the exposure to risk factors. Exposure to risk factors for solid tumors and the decrease in practices that reduce this risk are expected to increase the incidence of solid tumors. Solid tumors are associated with modifiable risk factors such as alcohol consumption, physical inactivity, weight gain, and obesity.
For instance, the use of hormonal therapy after menopause and the use of contraceptives are potential risks for developing breast cancer.
The consumption of three to six glasses of alcoholic drinks per week can increase the risk of developing the disease by 15%. Also, women with estrogen-positive breast cancer who consume one glass of any alcoholic drink per day have a 90% higher risk of developing second cancer.
Further, the report states that one challenge that could hamper market growth is the patent expiration on top-selling drugs.
- F. Hoffmann-La Roche
- Johnson & Johnson
Key Topics Covered:
Part 01: Executive summary
Part 02: Scope of the report
Part 03: Market research methodology
Part 04: Introduction
Part 05: Cost analysis
Part 06: Pipeline portfolio
Part 07: Market landscape
Part 08: Market segmentation by molecule type
Part 09: Market segmentation by type of therapy
Part 10: Market segmentation by disease
Part 11: Geographical segmentation
Part 12: Market drivers
Part 13: Impact of drivers
Part 14: Market challenges
Part 15: Impact of drivers and challenges
Part 16: Market trends
Part 17: Vendor landscape
For more information visit http://www.researchandmarkets.com/research/zlnv52/global_solid
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-and-markets---global-solid-tumors-drugs-market-2016-2020---key-vendors-are-f-hoffmann-la-roche-novartis-celgene-johnson--johnson-pfizer--bms-300298792.html
SOURCE Research and Markets